Novartis Ag Adr Stock Analysis
NVS Stock | USD 104.28 0.43 0.41% |
Novartis AG ADR is overvalued with Real Value of 97.57 and Target Price of 112.75. The main objective of Novartis stock analysis is to determine its intrinsic value, which is an estimate of what Novartis AG ADR is worth, separate from its market price. There are two main types of Novartis' stock analysis: fundamental analysis and technical analysis.
The Novartis stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Novartis is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Novartis Stock trading window is adjusted to America/New York timezone.
Novartis |
Novartis Stock Analysis Notes
The book value of the company was now reported as 21.67. The company recorded earning per share (EPS) of 5.72. Novartis AG ADR last dividend was issued on the 7th of March 2024. The entity had 1116:1000 split on the 9th of April 2019. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 108000 people. To find out more about Novartis AG ADR contact Richard Saynor at 41 61 324 1111 or learn more at https://www.novartis.com.Novartis Quarterly Total Revenue |
|
Novartis AG ADR Investment Alerts
Novartis AG ADR generated a negative expected return over the last 90 days | |
Novartis AG ADR has a strong financial position based on the latest SEC filings | |
Latest headline from seekingalpha.com: Novartis buys gene therapy developer Kate |
Novartis AG ADR Upcoming and Recent Events
31st of January 2024 Upcoming Quarterly Report | View | |
23rd of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
31st of January 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Novartis Largest EPS Surprises
Earnings surprises can significantly impact Novartis' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
1997-04-22 | 1997-03-31 | 0.45 | 0.52 | 0.07 | 15 | ||
2007-10-18 | 2007-09-30 | 0.76 | 0.68 | -0.08 | 10 | ||
2007-01-18 | 2006-12-31 | 0.78 | 0.7 | -0.08 | 10 |
Novartis Environmental, Social, and Governance (ESG) Scores
Novartis' ESG score is a quantitative measure that evaluates Novartis' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Novartis' operations that may have significant financial implications and affect Novartis' stock price as well as guide investors towards more socially responsible investments.
Novartis Thematic Classifications
In addition to having Novartis stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
HealthcareUSA Equities from Healthcare industry as classified by Fama & French | ||
CompulsionAddiction driven consumer products and services |
Novartis Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Renaissance Technologies Corp | 2024-09-30 | 2.3 M | Cullen Capital Management, Llc | 2024-09-30 | 2.3 M | Wells Fargo & Co | 2024-06-30 | 2.1 M | Envestnet Asset Management Inc | 2024-09-30 | 2 M | Bank Of New York Mellon Corp | 2024-06-30 | 1.9 M | Blackrock Inc | 2024-06-30 | 1.9 M | State Street Corp | 2024-06-30 | 1.8 M | Northern Trust Corp | 2024-09-30 | 1.7 M | Fisher Asset Management, Llc | 2024-09-30 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 14.8 M | Dodge & Cox | 2024-09-30 | 12.2 M |
Novartis Market Capitalization
The company currently falls under 'Mega-Cap' category with a total capitalization of 211.15 B.Novartis Profitablity
The company has Net Profit Margin of 0.35 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.33 %, which entails that for every 100 dollars of revenue, it generated $0.33 of operating income.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.27 | 0.28 | |
Return On Capital Employed | 0.13 | 0.14 | |
Return On Assets | 0.15 | 0.11 | |
Return On Equity | 0.32 | 0.33 |
Management Efficiency
Novartis AG ADR has Return on Asset of 0.1059 % which means that on every $100 spent on assets, it made $0.1059 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2879 %, implying that it generated $0.2879 on every 100 dollars invested. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novartis' Return On Tangible Assets are comparatively stable compared to the past year. Return On Capital Employed is likely to gain to 0.14 in 2024, whereas Return On Assets are likely to drop 0.11 in 2024. At this time, Novartis' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 73.2 B in 2024, whereas Other Current Assets are likely to drop slightly above 2.3 B in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 22.37 | 17.84 | |
Tangible Book Value Per Share | 0.89 | 0.85 | |
Enterprise Value Over EBITDA | 12.26 | 13.75 | |
Price Book Value Ratio | 4.52 | 3.23 | |
Enterprise Value Multiple | 12.26 | 13.75 | |
Price Fair Value | 4.52 | 3.23 | |
Enterprise Value | 223.9 B | 116 B |
The leadership approach at Novartis' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Dividend Yield 0.0362 | Operating Margin 0.3347 | Profit Margin 0.3525 | Forward Dividend Yield 0.0362 | Beta 0.505 |
Technical Drivers
As of the 25th of November, Novartis secures the Risk Adjusted Performance of (0.14), mean deviation of 0.6853, and Standard Deviation of 0.9732. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Novartis AG ADR, as well as the relationship between them. Please verify Novartis AG ADR market risk adjusted performance and treynor ratio to decide if Novartis AG ADR is priced some-what accurately, providing market reflects its recent price of 104.28 per share. Given that Novartis AG ADR has information ratio of (0.32), we recommend you to check Novartis's last-minute market performance to make sure the company can sustain itself at a future point.Novartis AG ADR Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Novartis middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Novartis AG ADR. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Novartis Outstanding Bonds
Novartis issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Novartis AG ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Novartis bonds can be classified according to their maturity, which is the date when Novartis AG ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
NOVARTIS CAPITAL P Corp BondUS66989HAS76 | View | |
NOVARTIS CAPITAL P Corp BondUS66989HAQ11 | View | |
NOVARTIS CAPITAL P Corp BondUS66989HAR93 | View | |
NOVARTIS CAPITAL P Corp BondUS66989HAP38 | View | |
NOVARTIS CAP P Corp BondUS66989HAN89 | View | |
NOVARTIS CAP P Corp BondUS66989HAK41 | View | |
NOVARTIS CAP P Corp BondUS66989HAJ77 | View | |
US66981QAA40 Corp BondUS66981QAA40 | View |
Novartis Predictive Daily Indicators
Novartis intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Novartis stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Novartis Corporate Filings
6K | 29th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 17th of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
6K | 18th of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 17th of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
16th of September 2024 Other Reports | ViewVerify | |
F3 | 15th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13th of August 2024 Other Reports | ViewVerify | |
6K | 8th of August 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Novartis Forecast Models
Novartis' time-series forecasting models are one of many Novartis' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Novartis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Novartis Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Novartis prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Novartis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Novartis. By using and applying Novartis Stock analysis, traders can create a robust methodology for identifying Novartis entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.20 | 0.25 | |
Operating Profit Margin | 0.21 | 0.18 | |
Net Profit Margin | 0.32 | 0.17 | |
Gross Profit Margin | 0.73 | 0.78 |
Current Novartis Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Novartis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Novartis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
112.75 | Buy | 12 | Odds |
Most Novartis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Novartis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Novartis AG ADR, talking to its executives and customers, or listening to Novartis conference calls.
Novartis Stock Analysis Indicators
Novartis AG ADR stock analysis indicators help investors evaluate how Novartis stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Novartis shares will generate the highest return on investment. By understating and applying Novartis stock analysis, traders can identify Novartis position entry and exit signals to maximize returns.
Begin Period Cash Flow | 7.5 B | |
Long Term Debt | 18.4 B | |
Common Stock Shares Outstanding | 2.1 B | |
Total Stockholder Equity | 46.7 B | |
Total Cashflows From Investing Activities | 5.6 B | |
Tax Provision | 1.4 B | |
Quarterly Earnings Growth Y O Y | 0.846 | |
Property Plant And Equipment Net | 10.9 B | |
Cash And Short Term Investments | 14.4 B | |
Cash | 13.4 B | |
Accounts Payable | 4.9 B | |
Net Debt | 13 B | |
50 Day M A | 111.8672 | |
Total Current Liabilities | 26.4 B | |
Other Operating Expenses | 36.9 B | |
Non Current Assets Total | 69.5 B | |
Forward Price Earnings | 12.7389 | |
Non Currrent Assets Other | 2.2 B | |
Stock Based Compensation | 865 M |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.